Atlas Trials

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Clinical trial NCT02625168 · COMPLETED

Trial details

NCT number
NCT02625168
Sponsor
The University of Hong Kong
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer
Start date
2013-01-01
Primary completion
2014-09-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.